Personalis Unveils New Study Highlighting MRD Assay Potential in Immunotherapy Monitoring
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy PSNL?
Source: Newsfilter
- Significant Findings: The study published by Personalis demonstrates that the NeXT Personal® assay possesses ultrasensitive molecular residual disease (MRD) detection capabilities, crucial for monitoring immunotherapy responses and improving patient survival rates.
- Early Response Identification: The research indicates that molecular responses can be detected a median of 23 days after initiating immunotherapy, with patients showing early responses experiencing significantly longer progression-free survival, underscoring the assay's clinical intervention importance.
- Lead Time Over Imaging: For patients whose disease progressed, NeXT Personal identified molecular progression a median of 161 days before imaging, highlighting its potential value in early intervention and possibly altering clinical decision-making.
- Survival Rate Enhancement: The study reveals that patients achieving molecular complete response had seven times higher overall survival compared to those who did not, emphasizing the critical role of ultrasensitive ctDNA testing in cancer treatment and potentially offering better therapeutic options for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 11.17 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.415
Low
10.00
Averages
11.17
High
12.00
Current: 7.415
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Personalis Unveils New Study Highlighting MRD Assay Potential in Immunotherapy Monitoring
- Significant Findings: The study published by Personalis demonstrates that the NeXT Personal® assay possesses ultrasensitive molecular residual disease (MRD) detection capabilities, crucial for monitoring immunotherapy responses and improving patient survival rates.
- Early Response Identification: The research indicates that molecular responses can be detected a median of 23 days after initiating immunotherapy, with patients showing early responses experiencing significantly longer progression-free survival, underscoring the assay's clinical intervention importance.
- Lead Time Over Imaging: For patients whose disease progressed, NeXT Personal identified molecular progression a median of 161 days before imaging, highlighting its potential value in early intervention and possibly altering clinical decision-making.
- Survival Rate Enhancement: The study reveals that patients achieving molecular complete response had seven times higher overall survival compared to those who did not, emphasizing the critical role of ultrasensitive ctDNA testing in cancer treatment and potentially offering better therapeutic options for patients.
See More
Personalis to Attend BTIG MedTech Conference
- Management Attendance: Personalis, Inc.'s management team will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026, at the Cliff Lodge in Snowbird, Utah, aiming to showcase the company's leadership in precision oncology.
- Precision Oncology Innovation: Personalis is transforming cancer management through breakthrough personalized testing, combining tumor and normal profiling to deliver advanced insights that adapt as cancer evolves, thereby enhancing patient treatment outcomes.
- Product Advantages: The company's products focus on detecting minimal residual disease (MRD) and recurrence at the earliest timepoints, enabling targeted therapy selection based on ultra-comprehensive genomic profiling, which enhances biomarker strategies for drug development and strengthens market competitiveness.
- Company Background: Based in Fremont, California, Personalis is dedicated to reshaping cancer management paradigms through personalized testing, guiding care from biopsy through the patient's entire lifecycle.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
ARK Invest Focuses on Innovation Themes, Increases Stake in Komatsu and Others
- Focus on Innovation: ARK Invest repositioned its portfolio last week towards long-term innovation themes such as advanced air mobility, autonomous transport, and gene editing, demonstrating a strong confidence in future technologies.
- Key Stake Increases: The ARK Space Exploration & Innovation ETF (ARKX) added approximately 49,000 shares of Komatsu (KMTUY), a company heavily invested in automation and smart infrastructure, which is expected to enhance its market competitiveness.
- Healthcare Investments: ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) increased stakes in Intellia Therapeutics (NTLA), focusing on CRISPR-based therapies, indicating ARK's commitment to precision medicine and gene editing sectors.
- Reduction in Mature Tech: ARK sold around 19.3 million shares of Meta Platforms (META) worth approximately $12.7 million in the past week, reflecting a cautious stance towards mature tech companies, which may impact short-term returns.
See More
ARK Genomic Revolution ETF Falls 2.5%, Personalis Drops 9.8%
- ETF Underperformance: The ARK Genomic Revolution ETF fell approximately 2.5% during Thursday afternoon trading, indicating a decline in market confidence in the sector, which may affect future capital inflows.
- Stock Weakness: Within the ETF, shares of Personalis dropped about 9.8%, while Absci fell approximately 8.6%, suggesting that these companies' performances failed to meet market expectations, potentially leading investors to reassess their investment value.
- Market Sentiment Fluctuation: The overall poor performance of the ETF may trigger investor concerns regarding the genomics sector, which could impact the financing capabilities and market positioning of related companies.
- Uncertain Industry Outlook: As competition intensifies in the genomics industry, the decline of the ARK ETF may signal a decrease in investor confidence regarding the sector's future growth potential, thereby affecting the overall strategic development of the industry.
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Personalis Unveils New Study Highlighting MRD Assay Potential in Immunotherapy Monitoring
- Significant Findings: The study published by Personalis demonstrates that the NeXT Personal® assay possesses ultrasensitive molecular residual disease (MRD) detection capabilities, crucial for monitoring immunotherapy responses and improving patient survival rates.
- Early Response Identification: The research indicates that molecular responses can be detected a median of 23 days after initiating immunotherapy, with patients showing early responses experiencing significantly longer progression-free survival, underscoring the assay's clinical intervention importance.
- Lead Time Over Imaging: For patients whose disease progressed, NeXT Personal identified molecular progression a median of 161 days before imaging, highlighting its potential value in early intervention and possibly altering clinical decision-making.
- Survival Rate Enhancement: The study reveals that patients achieving molecular complete response had seven times higher overall survival compared to those who did not, emphasizing the critical role of ultrasensitive ctDNA testing in cancer treatment and potentially offering better therapeutic options for patients.
See More
Personalis to Attend BTIG MedTech Conference
- Management Attendance: Personalis, Inc.'s management team will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026, at the Cliff Lodge in Snowbird, Utah, aiming to showcase the company's leadership in precision oncology.
- Precision Oncology Innovation: Personalis is transforming cancer management through breakthrough personalized testing, combining tumor and normal profiling to deliver advanced insights that adapt as cancer evolves, thereby enhancing patient treatment outcomes.
- Product Advantages: The company's products focus on detecting minimal residual disease (MRD) and recurrence at the earliest timepoints, enabling targeted therapy selection based on ultra-comprehensive genomic profiling, which enhances biomarker strategies for drug development and strengthens market competitiveness.
- Company Background: Based in Fremont, California, Personalis is dedicated to reshaping cancer management paradigms through personalized testing, guiding care from biopsy through the patient's entire lifecycle.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
ARK Invest Focuses on Innovation Themes, Increases Stake in Komatsu and Others
- Focus on Innovation: ARK Invest repositioned its portfolio last week towards long-term innovation themes such as advanced air mobility, autonomous transport, and gene editing, demonstrating a strong confidence in future technologies.
- Key Stake Increases: The ARK Space Exploration & Innovation ETF (ARKX) added approximately 49,000 shares of Komatsu (KMTUY), a company heavily invested in automation and smart infrastructure, which is expected to enhance its market competitiveness.
- Healthcare Investments: ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) increased stakes in Intellia Therapeutics (NTLA), focusing on CRISPR-based therapies, indicating ARK's commitment to precision medicine and gene editing sectors.
- Reduction in Mature Tech: ARK sold around 19.3 million shares of Meta Platforms (META) worth approximately $12.7 million in the past week, reflecting a cautious stance towards mature tech companies, which may impact short-term returns.
See More
ARK Genomic Revolution ETF Falls 2.5%, Personalis Drops 9.8%
- ETF Underperformance: The ARK Genomic Revolution ETF fell approximately 2.5% during Thursday afternoon trading, indicating a decline in market confidence in the sector, which may affect future capital inflows.
- Stock Weakness: Within the ETF, shares of Personalis dropped about 9.8%, while Absci fell approximately 8.6%, suggesting that these companies' performances failed to meet market expectations, potentially leading investors to reassess their investment value.
- Market Sentiment Fluctuation: The overall poor performance of the ETF may trigger investor concerns regarding the genomics sector, which could impact the financing capabilities and market positioning of related companies.
- Uncertain Industry Outlook: As competition intensifies in the genomics industry, the decline of the ARK ETF may signal a decrease in investor confidence regarding the sector's future growth potential, thereby affecting the overall strategic development of the industry.
See More
